Exhaled NO Testing in Filariasis

Filariasis Clinical Trial

Official title:

Exhaled NO Testing in Filariasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01628497
• Other study ID #: Fil-01
• Status: Completed
• Phase: N/A
• First received: June 22, 2012
• Last updated: April 5, 2017
• Start date: May 2012
• Est. completion date: March 2014

Study information

• Verified date: April 2017
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is looking at the difference in exhaled nitric oxide levels in patients with and without laboratory evidence of filariasis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

1. Age 6 years or older of either gender

2. Patients presenting with pulmonary symptoms a. Confirmed or suspected asthma patients: i. Patients presenting with symptoms consistent with an acute exacerbation of asthma, including:

1. Wheezing 2. Shortness of breath 3. Chest tightness 4. Cough ii. Disposition to the asthma room after triage and physician evaluation (disposition to other areas of the A&E allowed if due to no available space in the asthma room) iii. Patients are potentially eligible with or without a past history of health care provider diagnosed asthma iv. Patients are potentially eligible regardless of the number of previous episodes of wheezing (i.e. patients with a first episode of bronchospasm are potentially eligible) v. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:

1. They have a dry cough (no production of purulent sputum)

2. They have bronchospasm as manifested by wheezing or need for salbutamol (albuterol) breathing treatments vi. Patients with wheezing are not eligible if they:

1. Have purulent sputum production 2. Have known or suspected:

a. Tuberculosis b. Immunodeficiency c. Congestive heart failure d. Foreign body aspiration b. Patients presenting with a chief complaint of cough: i. Potentially eligible patients will have a cough of greater than one week (seven days) duration ii. Asthma room disposition is not required for these subjects iii. If suspected or documented to have pneumonia or a pulmonary infiltrate, patients are potentially eligible if:

1. They have a dry cough (no production of purulent sputum) iv. Patients with cough are not eligible if:

1. Have purulent sputum production

2. Have known or suspected:

1. Tuberculosis

2. Immunodeficiency

3. Congestive heart failure

4. Foreign body aspiration

3. Patients will be medically stable at the time of the consent process (see exclusion criteria below)

4. A minimum of 2 years of continuous residence in Guyana at the time of enrollment, exclusive of short trips out of the country (at least 21 of previous 24 months physically in Guyana)

5. English speaking

Exclusion Criteria:

1. Patients less than 6 years of age

2. Patients who do not consent to the study

3. Children (<18 years) without a parent/guardian present

4. Prisoners

5. Patients who appear to be medically or psychologically unstable or felt to be otherwise inappropriate for study enrollment, in the opinion of the investigator or any treating health care provider. This determination will be made on an individual basis, but some of the general criteria to be used in making this determination will be:

i. The patient appears to be in significant pain ii. The patient appears acutely ill

• severe respiratory distress, diaphoretic, altered mental status, active bleeding, actively vomiting, etc.

iii. Those with respiratory difficulty to the point they cannot speak in complete sentences iv. Chief complaint of sexual assault v. The patient appears acutely intoxicated vi. The patient displays agitated, nervous, restless, or other behavior suggestive of an uncontrolled psychiatric emergency

6. Patients with pulmonary findings felt to be secondary to congestive heart failure, foreign body, bacterial pneumonia, tuberculosis or other clearly defined cause

7. Non-English speaking patients

8. Patients without at least 2 years of residence (exclusive of short trips abroad, total of 21 of 24 previous months physically in Guyana) in Guyana at the time of enrollment

Related Conditions & MeSH terms

• Filariasis

Locations

Country	Name	City	State
Guyana	Georgetown Public Hospital Corporation	Georgetown	Region 4

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

Guyana,